Thrivent Financial for Lutherans Sells 49,495 Shares of Henry Schein, Inc. $HSIC

Thrivent Financial for Lutherans cut its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 42.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 68,043 shares of the company’s stock after selling 49,495 shares during the period. Thrivent Financial for Lutherans’ holdings in Henry Schein were worth $4,970,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Artisan Partners Limited Partnership grew its position in Henry Schein by 0.9% during the 2nd quarter. Artisan Partners Limited Partnership now owns 6,462,204 shares of the company’s stock worth $472,064,000 after acquiring an additional 55,653 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares in the last quarter. Schroder Investment Management Group boosted its stake in shares of Henry Schein by 149.3% during the second quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock valued at $114,243,000 after purchasing an additional 936,471 shares in the last quarter. Norges Bank bought a new stake in shares of Henry Schein during the second quarter worth about $89,476,000. Finally, Swedbank AB increased its stake in shares of Henry Schein by 30.9% in the second quarter. Swedbank AB now owns 1,156,398 shares of the company’s stock valued at $84,475,000 after buying an additional 272,913 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC stock opened at $77.35 on Friday. The firm has a 50 day moving average of $70.43 and a 200-day moving average of $69.77. The company has a market cap of $9.11 billion, a price-to-earnings ratio of 24.48, a price-to-earnings-growth ratio of 2.36 and a beta of 0.89. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.11. The business had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. On average, equities analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on HSIC. Barrington Research set a $79.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Wells Fargo & Company raised their price target on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price objective on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Morgan Stanley increased their price objective on Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a report on Wednesday, November 5th. Finally, Barclays initiated coverage on Henry Schein in a report on Monday, December 8th. They set an “overweight” rating and a $86.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $76.92.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.